Annamaria Mascolo
Overview
Explore the profile of Annamaria Mascolo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mascolo A, DellAnno I, Dondi L, Scavone C, Capuano A, Giordano M, et al.
J Oncol Pharm Pract
. 2025 Mar;
:10781552251327117.
PMID: 40080877
BackgroundCompassionate drug use (CDU) is a topic of debate in the scientific community characterized by a lack of information, especially in the onco-hematology area.AimThe Compass-O study aimed to provide updated...
2.
Di Napoli R, Balzano N, Ruggiero R, Mascolo A, Scavone C, Mauro G, et al.
Expert Opin Drug Saf
. 2024 Dec;
1-10.
PMID: 39696955
Background: Concern about post-CAR T-cell lymphomas has recently emerged. Analysis of pharmacovigilance data contributes to continuous safety monitoring, especially for newly authorized medicines, like CAR-T therapies. Research Design And Methods:...
3.
Mascolo A, Zinzi A, Gaio M, Ruggiero D, Scavone C, Rossi F, et al.
Pharmacol Rep
. 2024 Oct;
77(1):274-286.
PMID: 39438404
Introduction: Dapagliflozin and empagliflozin are sodium-glucose cotransporter-2 (SGLT2) inhibitors initially approved for the treatment of type 2 diabetes mellitus (DM), and later for heart failure (HF). Considering this differential therapeutic...
4.
Balzano N, Mascolo A, Di Napoli R, Colapietra F, Di Domenico M, Capuano A, et al.
J Pers Med
. 2024 Sep;
14(9).
PMID: 39338215
Dexmedetomidine, a selective α2-adrenergic agonist, is favoured in intensive care for its minimal respiratory depression. This study evaluated the reporting frequency of rhabdomyolysis with dexmedetomidine compared to midazolam and propofol...
5.
Oliva A, Scavone C, Riccardi C, Bernardi F, Salvo F, Mascolo A
Clin Transl Oncol
. 2024 Sep;
PMID: 39292389
Purpose: In the last decade trastuzumab biosimilars became more and more frequent. Among their uses, from several years, they have been available in Europe for the treatment of HER2-positive metastatic...
6.
DellAnno I, Dondi L, Esposito I, Mascolo A, Capuano A, De Marchi G, et al.
Clin Drug Investig
. 2024 Jul;
44(8):577-586.
PMID: 39031332
Background: Compassionate drug use (CDU) provides early access to not yet authorised medicines and is funded by pharmaceutical companies. The observational retrospective study Compass-O monitored the CDU of onco-haematological drugs,...
7.
Ruggiero R, Mascolo A, Spezzaferri A, Carpentieri C, Torella D, Sportiello L, et al.
Pharmaceuticals (Basel)
. 2024 Feb;
17(2).
PMID: 38399362
Background: A potential risk of suicide associated with liraglutide or semaglutide treatments has recently emerged. Therefore, we decided to investigate the reporting probability of suicidal events among glucagon-like peptide-1 receptor...
8.
Mascolo A, Rafaniello C, Mauro G, Ruggiero D, Campitiello M, Donniacuo M, et al.
Front Pharmacol
. 2023 Nov;
14:1245642.
PMID: 38027019
The risk of falls and bone fractures with sodium-glucose co-transporter-2 (SGLT2) inhibitors has been characterized by conflicting evidence. Therefore, we decided to investigate the reporting probability of falls and fractures...
9.
Sportiello L, Di Napoli R, Balzano N, Mascolo A, Ruggiero R, Di Costanzo L, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004432
(1) Background: The purpose of study was to compare the safety profile of glatiramer with natalizumab, alemtuzumab and ocrelizumab in pregnant and lactating women affected by multiple sclerosis (MS). (2)...
10.
Bernardi F, Mascolo A, Sarno M, Capoluongo N, Trama U, Ruggiero R, et al.
Vaccines (Basel)
. 2023 Oct;
11(10).
PMID: 37896978
Introduction: Real-world safety studies can provide important evidence on the thromboembolic risk associated with COVID-19 vaccines, considering that millions of people have been already vaccinated against COVID-19. In this study,...